Cell and Gene Therapy Manufacturing Carries an Outsized Documentation Burden
Cell and gene therapy (CGT) manufacturing is among the most documentation-intensive sectors in the biopharmaceutical industry. Every batch produced under current Good Manufacturing Practice (cGMP) conditions requires a complete batch record—a compilation of executed instructions, in-process testing results, equipment logs, and deviation reports that can run hundreds of pages for a single lot. The FDA's 2024 Center for Biologics Evaluation and Research (CBER) inspection data shows that incomplete batch records are the single most common finding in CGT facility inspections, cited in 41% of warning letters issued to the sector.
For a startup CGT manufacturer with a team of 20–40 people preparing for its first commercial license application or BLA filing, the administrative workload associated with batch documentation, regulatory submissions, and vendor management can overwhelm the operations team—especially during scale-up.
Batch Record Documentation Support: Keeping Manufacturing Compliant
A virtual assistant supporting batch record documentation does not perform the manufacturing steps—those require trained specialists. What a VA does is manage the administrative scaffolding around batch records: formatting master batch record templates per approved SOPs, tracking which batch records are in review, logging deviation and non-conformance reports, sending reminder notifications when batch record review windows are approaching their deadline, and maintaining a batch disposition tracker.
According to the International Society for Pharmaceutical Engineering (ISPE) 2025 Advanced Therapy Medicinal Product Manufacturing Survey, documentation review and approval cycles for CGT batch records average 12–18 days—with administrative delays (missing signatures, formatting errors, incomplete attachments) accounting for 35% of that time. A VA who manages the document routing workflow can compress those delays significantly.
Regulatory Filing Coordination for BLA and IND Amendments
CGT manufacturers in clinical or pre-commercial stages maintain active IND files with the FDA and, for international clinical trials, comparable dossiers with EMA and other health authorities. Each IND requires annual reports, safety reporting (IND safety reports for serious unexpected adverse events), and protocol amendment filings. As a company advances toward a BLA, the filing workload compounds further.
A virtual assistant assigned to regulatory filing coordination maintains a submission calendar with FDA deadlines, PDUFA dates, and CMC milestone commitments. They prepare eCTD submission packages under the direction of regulatory affairs staff, track acknowledgment receipts and deficiency letters, and coordinate cross-functional input gathering for annual reports. The FDA's CBER reported in 2025 that BLA submission timelines for CGT products averaged 14 months from filing to approval decision, with pre-submission preparation consuming 40% of that window—time that systematic VA coordination can help compress.
Vendor Qualification Admin: The Hidden Compliance Workload
CGT manufacturing depends on a tightly controlled supply chain—raw materials, cell culture media, viral vector components, and single-use equipment—all of which must come from qualified vendors. Vendor qualification requires collecting and reviewing quality agreements, auditing documentation, maintaining qualification status records, and managing re-qualification cycles when vendor processes change.
A virtual assistant handling vendor qualification admin maintains the approved vendor list with qualification expiry dates, sends re-qualification reminders, collects updated certificates of analysis and quality agreements, and tracks audit finding remediation. According to the Parenteral Drug Association's 2024 Advanced Therapy Supply Chain Survey, 29% of CGT manufacturing delays were linked to unqualified or lapsed vendor qualifications—a failure mode that systematic VA-managed tracking directly prevents.
Building a VA-Supported Quality Operations Model
The most effective deployment model for a CGT manufacturer is to integrate the VA into the quality management system workflow as a document control and coordination resource. This means the VA works within the electronic quality management system (eQMS), understands the document hierarchy, and can manage routine tasks like:
- Change control coordination: Routing change control requests for review, tracking approvals
- Training record maintenance: Confirming that personnel training completions are logged in the QMS
- Audit preparation support: Assembling document packages for internal and external audits
These functions are critical but do not require advanced scientific training—they require precision, reliability, and familiarity with GMP documentation principles.
The Cost Argument in a Capital-Intensive Sector
CGT manufacturing facilities cost $50–$200 million to build and equip, and the per-dose cost of autologous therapies can exceed $400,000. In this capital-intensive environment, operational efficiency is not a secondary concern. A quality operations coordinator in a CGT company earns $80,000–$110,000 annually in the United States. A VA provides comparable administrative throughput at significantly lower cost, allowing a lean team to punch above its weight operationally.
Stealth Agents offers virtual assistants with life sciences manufacturing and GMP documentation experience who can support batch record coordination, regulatory filing workflows, and vendor qualification administration.
Sources
- FDA CBER, Inspection Findings for Advanced Therapy Products, 2024
- ISPE, Advanced Therapy Medicinal Product Manufacturing Survey, 2025
- FDA CBER, BLA Approval Timeline Analysis, 2025
- Parenteral Drug Association, Advanced Therapy Supply Chain Survey, 2024
- FDA, Code of Federal Regulations Title 21 Part 211, current edition
- Glassdoor, Quality Operations Compensation in Biopharma, 2025